Value of 18F-FDG PET/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype

de Mooij, Cornelis M.; Mitea, Cristina; Mottaghy, Felix M.; Smidt, Marjolein L.; van Nijnatten, Thiemo J. A.

doi:10.1186/s13550-021-00861-z

EJNMMI Research

Table 3 Differences in PET-parameters determined on the most FDG-avid axillary lymph node between axillary response groups

From: Value of ¹⁸F-FDG PET/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype

	All patients			All cN+ patients
	Axillary residual (n = 32)	No axillary residual (n = 37)	p-value	Axillary residual (n = 27)	Axillary pCR (n = 25)	p-value
All patients
SUV_max	5.09 0.56–17.63	3.43 0.64–18.67	0.126^a	5.86 1.17–17.63	5.28 1.51–18.67	0.301
SUV_mean	3.33 0.56–11.01	2.00 0.58–12.20	0.134^a	3.84 0.75–11.01	3.29 1.11–12.20	0.276
SUV_peak	4.10 0.78–12.57	2.75 0.60–16.17	0.121^a	4.42 0.78–12.57	3.73 1.44–16.17	0.451
MTV	1.70 0.51–15.74	1.73 0.19–9.47	0.947^a	1.98 0.51–15.74	2.30 0.45–9.47	0.755
TLG	6.41 0.36–120.88	3.74 0.12–115.53	0.336^a	7.26 1.16–120.88	8.92 0.64–115.53	0.791
NT-ratio	0.75 0.18–2.75	0.39 0.07–5.05	0.025^a	0.88 0.18–2.75	0.83 0.27–5.05	0.147
HER2-positive or TN patients
SUV_max	7.50 1.66–17.63	3.15 0.64–18.67	0.002^a	7.50 1.66–17.63	4.53 2.35–18.67	0.040^a
SUV_mean	4.69 1.23–11.01	2.07 0.58–12.20	0.002^a	4.69 1.23–11.01	3.01 1.46–12.20	0.031^a
SUV_peak	5.69 1.17–12.57	2.66 0.60–16.17	0.007^a	5.69 1.17–12.57	3.42 1.52–16.17	0.053^a
MTV	1.70 1.09–15.74	1.89 0.19–9.47	0.821^a	1.70 1.09–15.74	2.18 0.45–9.47	0.639^a
TLG	7.77 1.57–120.88	3.46 0.12–115.53	0.028^a	7.77 1.57–120.88	5.21 0.89–115.53	0.309^a
NT-ratio	1.18 0.18–2.47	0.39 0.11–2.74	0.008^a	1.18 0.18–2.47	0.56 0.27–2.74	0.083^a
ER+/HER2- patients
SUV_max	3.90 0.56–10.23	3.52 1.27–11.34	0.807^a	4.70 1.17–10.23	5.38 1.51–11.34	0.887^a
SUV_mean	2.50 0.56–6.71	2.00 1.00–7.21	0.807^a	3.20 0.75–6.71	3.41 1.11–7.21	0.887^a
SUV_peak	2.97 0.78–7.88	3.15 1.01–8.36	0.792^a	3.18 0.78–7.88	4.21 1.44–8.36	0.535^a
MTV	1.79 0.51–6.98	1.73 0.58–8.90	0.611^a	2.24 0.51–6.98	2.69 0.58–8.90	0.711^a
TLG	4.72 0.36–39.51	4.05 0.64–37.11	0.693^a	7.17 1.16–39.51	10.36 0.64–37.11	0.588^a
NT-ratio	0.64 0.18–2.75	0.46 0.07–5.05	0.848^a	0.85 0.24–2.75	1.04 0.39–5.05	0.759^a

Bold p-value indicates significance
FDG, ¹⁸F-fluorodeoxyglycose; HER2, human epidermal growth factor 2 receptor; TN, triple negative MTV, metabolic tumor volume; NT-ratio, nodal tumor ratio; pCR, pathologic complete response; SUV, standardized uptake values; TLG, total lesion glycolysis
^aMann-Whitney U test; all variables are displayed as median and range

Back to article page